Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients

Chronic Hepatitis B Clinical Trial

Official title:

A Multi-center, Open Label, Randomized Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Capsule Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT01436539
• Other study ID #: Ditan-2011-01
• Status: Not yet recruiting
• Phase: Phase 4
• First received: September 13, 2011
• Last updated: September 16, 2011
• Start date: September 2011
• Est. completion date: July 2013

Study information

• Verified date: September 2011
• Source: Capital Medical University
• Contact: n/a
• Is FDA regulated: No
• Health authority: China: Ethics Committee
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to evaluate the effects and safety of Adefovir Dipivoxil plus polyene phosphatidylcholine compared to Adefovir Dipivoxil alone in patients with chronic hepatitis B.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 300
• Est. completion date: July 2013
• Est. primary completion date: March 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Males and females between the age of 18 to 65 years with chronic hepatitis B.

• HBsAg positive for a minimum of 6 months.

• HBV DNA =4 log10 copies/ml, and = 6 log10 copies/mL

• Alanine aminotransferase (ALT) = 2 times the upper limit of normal(ULN) and =10 times ULN, and documented ALT abnormal within 6 month prior to the study screening.

• Had a liver biopsy performed within 6 months prior to randomization and has readable biopsy slides or agrees to have a biopsy performed prior to entry.

• Willing and able to provide written informed consent.

Exclusion Criteria:

• Received any nucleoside, nucleotide or interferon therapy within 6 months prior to the screening.

• Previous treatment with lamivudine, adefovir, entecavir or telbivudine and occurred viral breakthrough or genotype resistance.

• Received immunosuppressive agents or other immunoregulates (including thymosin),systemic cytotoxic drugs, other antiviral agents including Chinese herb medicine within 6 months prior to the screening.

• Active alcohol intake( more than 20g/d for female or more than 30g/d for male) or drug abuse within 1 year prior to screening. Alcohol or drug abuse considered by the investigator to be sufficient to hinder compliance with treatment, participation in the study or interpretation of results.

• ALT is greater than 10 times ULN at screening or has the history of transient decompensated liver disease due to acute exacerbation.

• Any of the laboratory test at screening as the following :

• serum creatinine > 1.5 mg/dl ;

• prothrombin time = 4 seconds prolonged or PTA <60%;

• serum albumin<32 g/L;

• serum bilirubin>3.0mg/dL;

• Hemoglobin<11g/dL(males) or <10 g/dL(females), white blood cells count<3.5 x 10^9/L, absolute neutrophil count <1.5 x 10^9/L, platelets<80 x 10^9/L.

• Patient is coinfected with HCV, HDV or HIV.

• Hepatocellular carcinoma (HCC), or the presence of a mass on imaging studies of the liver that is suggest of HCC, or an alpha-fetoprotein (AFP)> 500ng/mL.

• Decompensated liver disease as defined by serum bilirubin >3mg/dL, prothrombin time= 4 seconds prolonged, a serum albumin<32g/L, or a history of ascites, variceal bleeding or hepatic encephalopathy.

• Presence of other causes of liver disease (i.e.alcoholic liver disease,autoimmune hepatitis, hemochromatosis, Wilson disease, nonalcoholic steatohepatitis, alpha-1anti-trypsin deficiency).

• Any serious or active medical or psychiatric illnesses other than hepatitis B which, in the opinion of the investigator, would interfere with patient treatment, assessment or compliance with the protocol. This would include, may not limit to, renal, cardiac, pulmonary, vascular, neurogenic, digestive, metabolic (diabetes, thyroid disorders, adrenal disease), immunodeficiency disorders, active infection or cancer.

• BMI=30.

• Patient is pregnant or breast-feeding.

• Planned for liver transplantation or previous liver transplantation.

• Need take hepatotoxic drugs (e.g.,dapsone, erythromycin, fluconazole, rifampin, etc) and nephrotoxic drugs (e.g., NSAIDs, aminoglycosides, amphotericin B, foscarnet, etc.) for long time.

• History of hypersensitivity to nucleoside analogues.

• Previous (or planned) participation in an investigational trial involving administration of investigational compound within 12 weeks prior to the study screening.

• Poor compliance of the patient considered by investigator.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Chronic Hepatitis B
• Hepatitis
• Hepatitis A
• Hepatitis B
• Hepatitis B, Chronic
• Hepatitis, Chronic

Intervention

Drug:
• Adefovir Dipivoxil and polyene phosphatidylcholine
Adefovir Dipivoxil 10 mg once daily for 48 weeks plus Polyene phosphatidylcholine (PPC) 456 mg three times per day for 48 weeks
• Adefovir Dipivoxil
Adefovir Dipivoxil 10 mg once daily for 48 weeks

Locations

Country	Name	City	State
China	Beijing Ditan Hospital, Capital Medical University	Beijing

Sponsors (3)

Lead Sponsor	Collaborator
Jun Cheng	Fujian Cosunter Pharmaceutical Co. Ltd, Sanofi

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportions of subjects with histological response in treatment and control group.		at week 48	No
Secondary	Proportions of subjects in each group who achieve: HBV DNA < 300 copies/mL		at week 48	No
Secondary	Mean log10 reduction from baseline in HBVDNA		at week 12, 24, 48	No
Secondary	ALT normalization rate and range		at week 12 and 48	No
Secondary	Liver stiffness values reduction from baseline by Fibroscan		at week 48	No
Secondary	HBeAg loss and HBe seroconversion		at week 12 and 48	No
Secondary	HBsAg loss and HBs seroconversion		at week 12 and 48	No
Secondary	Improvement in symptoms score		at week 12, 24 and 48	No
Secondary	Frequency of adverse events		up to 60 weeks	Yes
Secondary	Frequency of serious adverse events		up to 60 weeks	Yes
Secondary	Frequency of discontinuations from study drug due to adverse events or laboratory abnormalities.		up to 60 weeks	Yes